Intellia Therapeutics (NTLA) investor relations material

Executive summary

• Achieved major clinical milestones in Phase 3 for lonvo-z (HAE) and nex-z (ATTR), with lonvo-z showing positive HAELO trial results and a rolling BLA submission underway; U.S. launch planned for H1 2027 if approved.

• FDA clinical holds on nex-z trials were lifted in early 2026; global enrollment resumed for MAGNITUDE and MAGNITUDE-2 studies, with MAGNITUDE-2 completion expected in H2 2026.

• Pre-commercial readiness for lonvo-z progressing, including team hiring, disease awareness initiatives, and engagement with HAE treatment centers.

• New genomic insights identified HLA C0501 allele as a risk factor for liver transaminase elevations in nex-z trials; mitigation strategies and HLA typing implemented.

• Ended Q2 2026 with $628.4M in cash, expected to fund operations into 2028.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $628.4M as of June 30, 2026, up from $605.1M at year-end 2025.

• Collaboration revenue was $7.7M for Q2 2026, down from $14.2M in Q2 2025, mainly due to reduced Regeneron revenue.

• R&D expenses decreased to $82.6M from $97M year-over-year, reflecting portfolio prioritization and lower external costs.

• G&A expenses rose to $37.8M from $27.2M, reflecting commercial infrastructure buildout and higher legal and stock-based compensation costs.

• Net loss for Q2 2026 was $106.6M, compared to $101.3M in the prior year quarter.

Outlook and guidance

• Cash runway expected to last at least into 2028, excluding any product or milestone revenues.

• FDA BLA acceptance for lonvo-z anticipated by year-end 2026, with U.S. commercial launch planned for H1 2027.

• MAGNITUDE-2 enrollment for nex-z in ATTRv-PN on track for completion in H2 2026.

• R&D expenses expected to decrease as focus shifts to high-value programs; commercial expenses to rise with launch preparations.